Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Massachusetts General Hospital
Updated on 4 October 2022
heart failure
antiretroviral agents
antiretroviral therapy
hiv viral load
heart disease
b-type natriuretic peptide
natriuretic peptide


Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure to improve cardiovascular health.


This is a 6-month study enrolling persons with HIV with no known history of heart disease. Participants will be screened for early signs of heart failure using cardiac ultrasound (cardiac transthoracic echocardiography or cardiac TTE). Those participants who have early changes in the structure and function of the heart and may be at future risk for heart failure will be enrolled into the study. Additional imaging of the heart will occur using cardiac magnetic resonance imaging (cardiac MRI). Following baseline studies, participants will either receive a medication called sacubitril/valsartan or placebo for 6 months. Sacubitril/valsartan in an FDA approved medication currently being used for heart failure with reduced ejection fraction in the general population, and we are evaluating whether this medication could be useful to reduce HIV-related heart failure with preserved ejection fraction. Sacubitril/valsartan is an oral medication taken twice daily that may block aldosterone hormone and increase natriuretic peptide hormone. Overall, this study aims to investigate the effect of sacubitril/valsartan on measures of heart disease related to inflammation, structure and function of the heart muscle in HIV using cardiac TTE and cardiac MRI imaging as well as blood markers of heart failure and inflammation.

Condition HIV/AIDS, Heart Failure With Preserved Ejection Fraction
Treatment Placebo Oral Tablet, Sacubitril-Valsartan 49-51Mg Oral Tablet
Clinical Study IdentifierNCT04153136
SponsorMassachusetts General Hospital
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Antiretroviral therapy use for >12 months
HIV Viral Load <200 copies/mL
Increased waist circumference based on NCEP criteria (male>102cm2 and female>88cm2) or increased waist to hip ratio based on WHO criteria (male>0.95 and female>0.80)
Left Ventricular Ejection Fraction>50%
Demonstration of one or more criteria for myocardial dysfunction on cardiac transthoracic echocardiogram, relevant to the progression of heart failure with preserved ejection fraction
Left Atrial Volume Index > 28 mL/m2
Global Longitudinal Strain <18%
Left Ventricular Mass Index > 95g/m2 (female), 115 g/m2 (male)

Exclusion Criteria

Known history of congestive heart failure or valvular disease
Recent cardiac event or stroke within 3 months
Current medication use acting along the RAAS pathway (ACEi, ARB, MR blockade, direct renin inhibitor), potassium (K) supplementation or diuretic
Angioedema to ACEi or ARB
SBP<100 mmHg
Medication suspected to have contraindication with active study drug
Steroid use within last 3 months
Uncontrolled diabetes requiring insulin and/or HbA1c > 7.5%
Creatinine (Cr)>1.5 mg/dL and estimated GFR<60 mL/min/1.73m2
K>5.5 mEq/L
Hemoglobin <10.0 g/dL
Known liver disease or ALT>3x upper limit normal
Pregnant, actively seeking pregnancy or breastfeeding
Estrogen, progestin derivative, or other sex steroid use within 3 months. Stable physiologic testosterone replacement (> 3 months) is acceptable
Current bacterial or other infection
Active substance abuse
Known reaction to gadolinium
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note